Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Lykke Midtbøll ØrnbjergCecilie Heegaard BraheJohan AsklingAdrian CiureaHerman MannFatos OnenEirik Klami KristianslundDan NordströmMaria Jose SantosCatalin CodreanuJuan Gómez-ReinoZiga RotarBjorn GudbjornssonDaniela Di GiuseppeMichael J NissenKarel PavelkaAhmet Merih BirlikTore KvienKari Kalervo EklundAnabela BarcelosRuxandra IonescuCarlos Sanchez-PiedraMatija TomsicÁrni Jón GeirssonAnne Gitte LoftIrene van der Horst-BruinsmaGareth T JonesFlorenzo IannoneLise HyldstrupNiels Steen KroghMerete Lund HetlandMikkel ØstergaardPublished in: Annals of the rheumatic diseases (2019)
A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.